Targeting histone deacetylases in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 months and a 5-year survival rate below 1%. Effective therapies for locally advanced or metastatic tumours are missing and curatively resected patients relapse in over 80% of the cases. Although histone deacet...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828843/ |